PRECIGEN Investors

Events & Presentations

Events & Presentations

Upcoming Events

More events are coming soon.

Past Events

Jun 03, 2024 at 6:00 PM CDT
Precigen webcast following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
May 31 - Jun 04, 2024
Abstract Selected for Late-Breaking Oral Presentation
  • June 3, 2024 | 8:00 AM - 9:30 AM CT
    PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients
    Abstract: 6015 | Rapid Oral Abstract Session - Head and Neck Cancer


Abstracts Selected for Poster Presentation

  • June 2, 2024 | 9:00 AM - 12:00 PM CT
    Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer
    Abstract: 6124 | Poster Session - Head and Neck Cancer
  • June 3, 2024 | 9:00 AM - 12:00 PM CT
    A Phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer
    Abstract 5623 | Poster Session - Gynecologic Cancer
Chicago, Illinois
Read More
May 15 - May 19, 2024
Precigen to participate in the 2024 COSM annual meeting taking place in Chicago from May 15 to May 19, 2024. On May 16 at 4:21 PM CT, Dr. Clint T. Allen, MD, Principal Investigator with the Section on Translational Tumor Immunology at the National Institutes of Health and a lead investigator for the PRGN-2012 clinical study, will present "Clinical Benefit following Adjuvant Therapeutic Vaccination with PRGN-2012 in Adult Patients with RRP."
Chicago, Illinois
Read More
Apr 09 - Apr 11, 2024
Helen Sabzevari, PhD, President and CEO of Precigen, to participate in two events at the 2024 Alliance for Regenerative Medicine Cell and Gene Meeting on the Med. She will participate as a panelist on a panel titled "A Forecast on the 2024 CGTx Landscape" on Tuesday, April 9, 2024 at 5:15 PM CET and provide a company presentation on Wednesday, April 10, 2024 at 2:30 PM CET.
Rome, Italy
Read More
Mar 25, 2024 at 1:00 PM EDT
Hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, the virtual fireside chat will include discussion of the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). Participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study. The call is available to institutional clients of Cantor Fitzgerald.
Read More
Nov 15, 2023 at 10:55 AM - 11:25 AM EST
Helen Sabzevari, PhD, President and CEO, Precigen, presented a company overview at the Stifel 2023 Healthcare Conference on November 14-15, 2023 in New York.
New York, NY
Read More
Oct 26, 2023 at 2:00 PM EDT
Helen Sabzevari, PhD, President and CEO, Precigen, participated in an Acute Myeloid Leukemia (AML) panel discussion on Thursday, October 26.
Virtual
Read More
Oct 24, 2023 at 5:00 PM - 7:00 PM CEST
Dr. Scott M. Norberg, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, presented an abstract titled, "Significant clinical benefit and enhanced T-cell responses with repeated administration of PRGN-2012, a novel gorilla adenoviral vector based immunotherapy, in adult patients with severe Recurrent Respiratory Papillomatosis.
Brussels, Belgium
Read More
Oct 11, 2023 at 3:30 PM PDT
Helen Sabzevari, PhD, President and CEO, Precigen, provided a company presentation on Wednesday, October 11 at 3:30 PM PT at the Cell & Gene Meeting on the Mesa conference taking place from October 10 to 12 in Carlsbad, California.
Carlsbad, CA
Read More
Jun 02 - Jun 06, 2023
  • Abstract #2628: Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C). Session Title: Developmental Therapeutics—Immunotherapy. Session Date and Time: June 3, 2023, 8:00 AM-11:00 AM CT.
  • Abstract #5590: Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. Session Title: Gynecologic Cancer. Session Date and Time: June 5, 2023, 1:15 PM-4:15 PM CT.
Read More
Apr 17, 2023 at 9:00 AM - 12:30 PM EDT

An abstract titled, "Next generation UltraCAR-T® cells with intrinsic checkpoint inhibition and overnight manufacturing overcome suppressive tumor microenvironment leading to sustained antitumor activity," was presented as a poster presentation.

Read More
Apr 04, 2023 at 8:30 AM EDT
Precigen hosted a conference call to provide business and clinical updates for recent announcements.
Read More